Workflow
Sage Therapeutics(SAGE) - 2021 Q3 - Earnings Call Presentation

Company Mission and Pipeline - Sage's mission is to be a top-tier biopharmaceutical company in the next 5 years, focusing on brain health[17] - The company has a rich pipeline across 3 franchises, including 3 late-stage programs and 5 NCE development programs across 12+ indications[17] - Sage aims for 2 or more IND-enabling programs per year by 2023[17] Zuranolone (SAGE-217) Development - Zuranolone is being developed for Major Depressive Disorder (MDD), Postpartum Depression (PPD), Treatment Resistant Depression, Generalized Anxiety Disorder, and Bipolar Depression[20, 21] - Clinical trials show consistent and rapid improvement in depressive symptoms with zuranolone[48] - Approximately 70% of participants with positive response to the initial 2-week course of zuranolone required only one or two courses of treatment during the 12-month SHORELINE study[54] - Shionogi's Phase 2 study in Japan achieved primary endpoints at both 20 mg and 30 mg doses, showing significant improvement over placebo from Day 3 to Day 15[71] SAGE-324 Development - SAGE-324 is being developed for Essential Tremor and Parkinson's Disease[23] - In an open-label, phase 1 study, a single dose of SAGE-324 resulted in nearly 50% tremor reduction in ET patients[97] - The KINETIC Study showed a statistically significant reduction from baseline in Upper Limb Tremor Score at Day 29 with SAGE-324[101] SAGE-718 Development - SAGE-718 is being developed for Huntington's Disease Cognitive Dysfunction, Parkinson's Disease Cognitive Dysfunction, and Alzheimer's Disease Mild Cognitive Impairment and Mild Dementia[24, 25] - In the Phase 2a open-label PARADIGM Study, patients with mild cognitive impairment due to Parkinson's disease showed performance improvements from baseline on multiple tests in the cognitive domain of executive function during the 14 days of treatment[132] Financial Position - Sage has over $1.8 billion in capital to fund efforts to accelerate and advance medicines[17] - The company anticipates a cash balance of more than $1.7 billion at the end of 2021[155] - Third quarter 2021 revenue from Zulresso was $1.4 million[155]